RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
Phase 1
Terminated
- Conditions
- Mitochondrial Diseases
- Registration Number
- NCT00060515
- Lead Sponsor
- Repligen Corporation
- Brief Summary
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method